ALX Oncology (ALXO) Set to Post Earnings on Friday

Key Points

• ALX Oncology is scheduled to report Q3 2026 results on Friday, November 6, at 8:30 a.m. ET. Analysts expect a loss of $0.15 per share, compared with the $0.13-per-share loss reported in the prior quarter, which beat estimates by $0.01.
• Analysts project full-year and next-year losses of $0.59 and $0.62 per share, respectively. The company is a clinical-stage biotechnology firm developing cancer immunotherapies, led by its investigational drug candidate evorpacept.
• ALXO shares recently traded at $1.22, with a 52-week range of $0.86 to $2.66 and a market capitalization of about $168.7 million. Despite one sell rating, the stock has a consensus “Moderate Buy” rating and a $4.60 price target.

ALX Oncology (NASDAQ:ALXO - Get Free Report) is expected to issue its Q3 2026 resultson Friday, November 6th. Analysts expect ALX Oncology to post earnings of ($0.15) per share for the quarter. Investors can check the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:30 AM ET.

ALX Oncology (NASDAQ:ALXO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01. On average, analysts expect ALX Oncology to post ($0.59) EPS for the current fiscal year and ($0.62) EPS for the next fiscal year.

ALX Oncology Trading Up 3.4%

Shares of ALXO stock opened at $1.22 on Friday. ALX Oncology has a 52-week low of $0.86 and a 52-week high of $2.66. The stock has a market cap of $168.70 million, a price-to-earnings ratio of -1.08 and a beta of 0.47. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.71. The firm has a fifty day moving average of $1.53 and a 200-day moving average of $1.82.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of ALX Oncology from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, September 17th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $4.60.

About ALX Oncology

ALX Oncology Holdings Inc NASDAQ: ALXO is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of cancer. The company's research centers on the CD47-SIRPα pathway, an immune checkpoint that cancer cells can use to evade detection and destruction by the immune system.

ALX Oncology's lead product candidate is evorpacept, also known as ALX148, an investigational protein designed to block CD47 while supporting the activity of therapeutic antibodies and other anti-cancer treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.